Resultados de la búsqueda 211-220 of 13189 for ethambutol

  1. Hematología - Ensayos clínicos - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    A Study Of The Drugs Selumetinib Vs. Carboplatin And Vincristine In Patients With Low-Grade Glioma. Rochester, Minn. This study aims to demonstrate that the ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

  6. Hematología - Ensayos clínicos - Mayo Clinic

    Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients ...

  7. Hidradenitis supurativa

    Yun E. Managing hidradenitis suppurativa in Black skin. Everyday Health. https://www.everydayhealth.com/hidradenitis-suppurativa/managing-hidradenitis- ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Rochester, Minn. This randomized phase II/III trial studies how well radiation therapy works when given together with cisplatin compared to docetaxel or ...

  9. Cirugía - Ensayos clínicos - Mayo Clinic

    This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...